Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Takara Bio Inc. ( (JP:4974) ).
Takara Bio reported a sharp downturn for the fiscal year ended March 31, 2026, with net sales falling 10.5% to ¥40.3 billion and a swing to an operating loss of ¥4.7 billion from a profit a year earlier. Profit attributable to owners of the parent deteriorated to a ¥9.6 billion loss, pushing return on equity into negative territory and reducing net assets per share as profitability and capital efficiency weakened.
Despite the earnings slump, total assets rose to ¥133.7 billion, driven in part by acquisition-related changes as Curio Biosciences, Inc. was newly consolidated, while cash outflows for investing expanded and dividends were suspended after a ¥17 per-share payout in the prior year. Looking ahead, Takara Bio forecasts modest revenue growth in fiscal 2027 but expects to remain loss-making, and is set to become a wholly owned subsidiary of parent Takara Holdings with its shares slated for delisting, reshaping the outlook for existing shareholders.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen940.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange that develops and sells research reagents, gene and cell therapy tools, and related services. The company focuses on life sciences and biomedical applications, supplying products to research institutions and biopharmaceutical customers in domestic and overseas markets.
Average Trading Volume: 774,273
Technical Sentiment Signal: Sell
Current Market Cap: Yen137.5B
For a thorough assessment of 4974 stock, go to TipRanks’ Stock Analysis page.